INTRODUCTION
Follow-up care is vital for many childhood cancer survivors due to the high risk of late effects (Geenen et al., 2007 , Hudson et al., 2013 , Oeffinger et al., 2006 . Follow-up offers potential for early detection and treatment of late effects and an opportunity to offer ageappropriate information about disease, treatment and a healthy lifestyle, practical advice about insurance, education or work, and psychosocial support (von der Weid and Wagner, 2003 , Gianinazzi et al., 2014 , Vetsch et al., 2015 . Published guidelines describe risk-based followup for childhood cancer survivors (Scottish Intercollegiate Guidelines Network (SIGN), 2004 , Stichting Kinderoncologie Nederland (SKION), 2010 , Children's Oncology Group, 2013 , and evidence-based, risk-adapted examinations. Despite the potential advantages of follow-up, attendance is often low (Michel et al., 2011b , Rebholz et al., 2011 , Essig et al., 2012 .
Previous studies highlighted the importance of assessing survivors' views and preferences about follow-up care (Aslett et al., 2007 , Earle et al., 2005 , Michel et al., 2009 ) to ensure it is relevant to survivors and consequently associated with good attendance. However, little is known about survivors' views of follow-up. They appear more interested in medical aspects of follow-up care such as checking for relapse, late effects and general health status, compared with gaining information about wider issues such as effects of cancer on employment or education, or health behaviour (Michel et al., 2009 , Eiser et al., 1996 . Organisational issues such as waiting time or length of consultation influenced satisfaction with care (Absolom et al., 2006) .
Other work has addressed preferences for different models of follow-up care (e.g. continuation of care with the paediatric oncologist, transfer to adult clinic or general practitioner (GP), or follow-up by telephone/questionnaire). Most survivors were satisfied with the care they received (Eiser et al., 1996 , Michel et al., 2011a , and wished to continue this model of follow-up (paediatric or adult clinic) (Absolom et al., 2006 , Michel et al., 2009 . Two qualitative studies concluded that GP follow-up was convenient but survivors were not confident about GPs knowledge about survivorship-specific care (Zebrack et al., 2004 , Earle et al., 2005 . However, most studies only included survivors attending follow-up appointments and therefore may not be relevant when considering views of survivors who do not attend follow-up care for whatever reason.
We aimed to describe 1) preferences for different organizational aspects and models of follow-up care among Swiss childhood cancer survivors (including both current attenders and nonattenders to follow-up care), and 2) characteristics of survivors associated with preferences for different models of care.
METHODS

Sample and procedure
The Swiss Childhood Cancer Registry (SCCR) is a population-based registry including all Swiss residents diagnosed before age 21 years with leukaemia, lymphoma, central nervous system (CNS) tumour, malignant solid tumour or Langerhans cell histiocytosis (Michel et al., 2007 , Michel et al., 2008 . The Swiss Childhood Cancer Survivor Study (SCCSS) is a nationwide, long-term follow-up study of all patients registered in the SCCR who were diagnosed between 1976-2005 and survived for ≥5 years (Kuehni et al., 2012a) .
For the baseline survey, between 2007-2009, all survivors aged older than 16 years at study received an information letter about the study from their treating institution. They were asked whether or not they wished to participate, their address, or if they required the baseline questionnaire in another language (German, French, and Italian) . Two weeks later, all survivors received a paper-based questionnaire (baseline) with a prepaid return envelope. Nonresponders received another questionnaire after 2 months and then were contacted by phone if they did not respond.
After approximately 3 years all participants who had completed the baseline questionnaire, were aged ≥18 years, and diagnosed with cancer at age ≤16 years between 1990-2005, received a follow-up questionnaire. Non-responders to this questionnaire were sent a reminder letter with a questionnaire and prepaid return envelope two months later. Because there were few Italian speaking participants, the second questionnaire was provided only in German and French. For the current study survivors whose parents completed the baseline questionnaire were excluded.
Ethics approval was provided through the general cancer registry of the SCCR (The Swiss Federal Commission of Experts for Professional Secrecy in Medical Research) and a non obstat statement (the ethical committee did not object to the running of the study) was obtained from the ethics committee of the canton of Bern. Participants gave informed consent for the study by returning the completed questionnaire.
The questionnaires
The baseline questionnaire was based on those used in the US and UK childhood cancer survivor studies (Robison et al., 2002 , Hawkins et al., 2008 , and covered the following topics: quality of life, somatic health, current medication, health service utilization, psychological distress, health behaviour and socio-economic information. The focus of the follow-up questionnaire was follow-up care and psychological outcomes.
Measurements
Baseline questionnaire
We assessed sex, migration background and selfreported late effects. We coded participants as having a migration background if they were not Swiss citizens, were not born in Switzerland, or at least one parent was not a Swiss citizen. We asked if survivors experience late effects from cancer or treatment (yes/no).
Follow-up questionnaire Outcome measures:
Follow-up attendance: We asked survivors if they still attended follow-up care (a) "I regularly attend follow-up", b) "I irregularly attend follow-up", c) "Follow-up is completed but I visit my treating doctor when I have questions", d) "Follow-up is completed and I never visit my former treating doctor". We coded (a) and (b) as attenders [1] , and (c) and (d) as non-attenders [0] . (Michel et al., 2009) : Survivors rated the importance of different reasons for attending follow-up (0="not at all important" to 3="very important"). Factor analysis revealed two scales: supportive care (get information about late effects, talk to staff who understand what I've been through, get advice about how to keep healthy, receive psychological support, get advice about everyday things) and clinical care (check the cancer has not come back, get reassurance about health, help clinic staff learn more about late effects, get the best medical care). Cronbach's alpha in our sample indicated a good internal consistency for both scales: supportive care: =0.80; clinical care =0.69.
Reasons for follow-up
What is important during appointments:
Survivors rated the importance of 10 organisational aspects of follow-up appointments (0="not at all important" to 3="very important"): Competent staff, being taken seriously, relationship quality between doctor and patient, insurance reimbursement, doctor continuity across appointments, no long waiting times, regular appointments, short and efficient consultation, nurse continuity across appointments, meeting other survivors.
What should be included in follow-up:
We asked about the importance of four clinical aspects (check that cancer has not come back, screen for late effects, provide information on potential late effects, other medical follow-up) and eight general aspects of follow-up (risk of diseases for my children, psychological counselling, availability of alternative medicine, information/counselling about sexuality, information about education / job, exchange with other survivors, support in spiritual aspects of life, other offers). Each aspect was rated on a 4 point scale (0="not at all important" to 3="very important").
Who should be involved in follow-up: Survivors rated how personally important it is that different medical and other specialists are involved in follow-up (0="not at all important" to 3="very important"): paediatric oncologist, general practitioner (GP), medical oncologist, fertility counselling, gynaecologist, endocrinologist, psychologist/psychiatrist, specialist nurse, radiotherapies, nutritional counselling, physiotherapist, geneticist, insurance counselling, social worker, career counselling, other specialist)
Where should follow-up be provided: We asked survivors' agreement (0="don't agree at all" to 3="completely agree") about the place where they would like to attend follow-up: a) at the paediatric hospital, where they were treated, b) a hospital for adults, c) a central, specialised follow-up clinic, d) their GP.
Preferences for models of follow-up care: We provided a short description of five different models of follow-up care: a) telephone/questionnaire based follow-up, b) GP follow-up, c) follow-up by paediatric oncologist who originally treated the patient, d) medical oncologist follow-up, e) hospital-based followup by a multidisciplinary team (MDT). For each model we asked survivors if this kind of followup would suit them, if they were afraid that health problems would not be detected, if they would not be satisfied with this kind of followup, and if they thought that this kind of followup was appropriate for their health (0="don't agree at all" to 3="completely agree"). Two items were reverse coded such that a higher score indicated higher positive agreement for the respective model (0-3). We calculated the mean of the four items to indicate agreement with each model. For model e) we asked 4 additional items, which were analysed separately (I can contact all specialists I need, I can be referred to the right specialist, follow-up is less personal, I don't know who is responsible for me).
Socio-demographic characteristics and psychological distress: Psychological distress: We used the Brief Symptom Inventory-18 (BSI-18) (Derogatis, 2000) and calculated scores for somatisation, depression, anxiety, and a Global Severity Index (GSI). Survivors rated how much they experienced each symptom during the 7 previous days on a 5-point scale (1="not at all" to 5="extremely"). Scale scores were converted into T-scores (mean=50; standard deviation (SD)=10). We created a case-indicator specifying survivors with high distress (T≥57 on at least 2 scales or the GSI) (Zabora et al., 2001 (Kuehni et al., 2012b) . Employment was coded as "employed", "in education" or "not employed". Partnership was coded as not having a partner vs. being in a partnership. Age at study was coded into ≤25 years and >25 years. The language was coded into German and French.
Data available from the SCCR Age at diagnosis was coded into 0-4 years, 5-9 years, 10+ years. Time since diagnosis was coded into 5-9 years, 10-14 years, 15+years. Diagnoses were classified according to the International Classification of Childhood Cancer-3 rd edition) (Steliarova-Foucher et al., 2005) . We recoded diagnoses into four major groups: leukaemia, lymphoma, CNS tumours and other solid tumours. Treatment was coded as surgery only, chemotherapy (without radiotherapy, may have had surgery), radiotherapy (may have had surgery and/or chemotherapy) and stem cell transplantation (SCT). Relapse and second malignancy were coded as yes/no.
Analyses
All analyses were performed using Stata 13.0 (StataCorp, College Station, TX). Numbers for each outcome vary because not all participants answered all questions. We used descriptive statistics and chi 2 -test to compare participants and non-participants in the study. To analyse aim 1 (preferences for different organizational aspects and models of follow-up care) we used means and proportions to describe different preferences for organizational aspects and models of follow-up care. Paired t-tests were used to compare the importance of clinical and supportive reasons, and as post-hoc test following Hotelling T-test for the comparison of more than two means. We used t-test and chi 2 -test to analyse differences in preferences between attenders and non-attenders to followup. To evaluate aim 2 (characteristics of survivors associated with preferences for different models of care), we used univariable and multivariable linear regression analyses using the mean satisfaction with each model of care as outcome. We ran separate regression analyses for each of the five described models of follow-up care. For multivariable regressions, we included all variables, which were significantly associated at p<0.05 in the univariable regressions for at least one of the follow-up models.
RESULTS
A total of 754 survivors were eligible for the follow-up questionnaire. We were able to contact 720 of these, and 314 were included in the study (43.6%; Figure 1 ). Participants' characteristics are described in Table 1 . Participants were more likely than non-participants to be female, and to have received radiotherapy, but less likely to have had surgery only.
1) Preferences for the organisation of followup care
Of the 314 responders, 150 (47.8%) reported they still attended follow-up (Table 1) .
Reasons for follow-up: Clinical reasons (mean=2.33, SD=0.58) were more important than supportive reasons (mean=1.61, SD=0.71; p<0.001; Figure 2 There was little difference in preferences for follow-up between attenders and non-attenders to follow-up (Online Table 1 ). Attenders reported slightly higher preference for clinical reasons for follow-up (p=0.014), to get the best medical care (p=0.009), and to talk to staff who understood what they had been through (p=0.008).
They also valued regular appointments (p<0.001) and information about education or work (p=0.001) higher than nonattenders. Attenders rated presence of endocrinologists (p=0.045) and other specialists (p=0.048) as more important than non-attenders.
Preferred model of follow-up care:
Survivors rated paediatric oncologist follow-up (mean=2.24, SD=0.72) and medical oncologist follow-up highest (mean=2.17, SD=0.69; p=0.087). Both these models were rated significantly higher than the other three models (all p<0.001, apart from medical oncologist compared to follow-up by multidisciplinary team [MDT]: p=0.031): MDT follow-up (mean=2.07, SD=0.73), GP follow-up (mean=1.90, SD=0.84), or follow-up by telephone/questionnaire (mean=1.06, SD=0.83). Regarding MDT followup, survivors liked being able to contact all specialists they needed (mean=2.27, SD=0.81), and could be referred to the right specialist (mean=2.28, SD=0.77). They did not agree that MDT follow-up might be less personal (mean=1.50, SD=1.04) or might mean they did not know who was responsible for their care (mean=1.13, SD=0.96).
2) Characteristics associated with preferences for different models of follow-up care
In univariable linear regression analyses we determined characteristics of survivors with different preferences for follow-up models (Online Table 2 ). Attenders rated follow-up by medical oncologist higher, and GP or phonefollow-up lower than non-attenders (Figure 4 ). Higher ratings of importance of clinical and supportive reasons were associated with all models: higher endorsement of importance of both clinical and supportive reasons were associated with lower rating of telephone/questionnaire and GP follow-up, and higher rating of the other models. Self-reported late effects were associated with lower rating of GP follow-up and higher rating of MDT followup. Survivors who received chemotherapy rated GP and paediatric oncologist follow-up highest and survivors undergoing other treatments rated them lower. Psychological distress was only associated with higher rating of importance of?MDT follow-up. Regarding sociodemographic characteristics, survivors older at study and those with higher education rated the paediatric oncologist follow-up lower, and French speaking survivors rated GP follow-up higher. Results of the multivariable linear regression remained similarly in the direction of the association. However, fewer characteristics remained statistically significant (Table 2) .
DISCUSSION
In our study, approximately half of responding survivors continued to attend follow-up. We found that clinical reasons for follow-up such as checking that cancer has not come back or being reassured about their health, were rated higher than supportive reasons. Survivors also expected competent staff at their follow-up, including paediatric or medical oncologists as well as general practitioners. Despite the age of these survivors (≥18 years) they valued going to the children's hospital for follow-up, but adult hospital or GP practice were rated similarly highly. Follow-up by paediatric or medical oncologist were the preferred follow-up models, particularly by those who rated clinical reasons for follow-up as very important.
The high endorsement of medical aspects of follow-up was similar to previous studies (Eiser et al., 1996 , Michel et al., 2009 , Zebrack et al., 2004 , Earle et al., 2005 . In a UK study using the same questions, we also found significantly higher importance given to clinical reasons than supportive reasons (Michel et al., 2009) . We also found that survivors wanted to discuss clinical topics such as their current health, late effects or medication, rather than general topics such as insurance or work-related issues. Our results also support findings of a US study showing that survivors wanted to be taken seriously by their doctors (Zebrack et al., 2004) .
In contrast to UK studies, where GP follow-up was rated comparable with telephone/questionnaire follow-up (Michel et al., 2009 , Eiser et al., 1996 , Swiss survivors rated GP follow-up highly, though not as much as paediatric or medical oncologist follow-up. The high preference for GP follow-up was also found in a qualitative study in the USA (Zebrack et al., 2004) ; however, survivors ranked follow-up by a "primary care physician knowledgeable and experienced in working with survivors" (p.849) highest. As GPs do not usually care for many childhood cancer survivors most will lack the required experience. A close collaboration between GP and a specialised late effects clinic might be a solution to this problem (Oeffinger, 2003 , Singer et al., 2013 . A Dutch study showed the potential of further education about late effects and follow-up care for GPs and that GPs were interested in such a programme (Blaauwbroek et al., 2007) .
Swiss survivors rated paediatric oncologist follow-up highest. This is in contrast to a US study, where survivors rated a programme staffed with a paediatric oncologist and nurse practitioner lower than primary care physician follow-up (Zebrack et al., 2004) . The high preference for the paediatric oncologist model in Switzerland might be due to the fact that survivors get high quality follow-up provided by their paediatric oncologist for at least 10 years after diagnosis. Therefore, the model describes a model with which they are familiar. Additionally, in Switzerland we have 9 specialised centres for paediatric oncology across the country, so that this model provides appropriate geographical access for most survivors.
Both attenders and non-attenders to follow-up reported similar preferences for the organisation of follow-up. However, attenders valued clinical reasons slightly higher than non-attenders. This may be one of the reasons why survivors continue to attend follow-up while those who consider clinical reasons to be less important do not. However, this needs to be addressed in future work as differences are small.
Expert opinions have often favoured centralised follow-up care by specialists (Essig et al., 2012) . Our results suggest that Swiss survivors are not favouring this model; a central specialised late effects clinic was rated lowest among the provided places. Although, given the size of Switzerland, distances to a central clinic would be relatively short for most survivors, this suggests that there is a preference for follow-up to be close to home. Organised transition from paediatric to adult oncology clinic seems a logical way forward and should contribute to optimal follow-up care.
A major strength of this study is the involvement of a population-based sample including both those who attend and those who do not attend follow-up care. In addition, we had access to established information on diagnosis, treatment and relapse from the Swiss Childhood Cancer Registry. We also assessed a wide range of different characteristics of follow-up care so that a detailed picture of survivors' needs could be drawn.
A limitation is that we could not include an objective measure of risk for late effects, apart from general indicators associated with diagnosis, treatment, relapse and second tumour. Depending on this risk, different follow-up models might be clinically preferable (Wallace et al., 2001) . For example, survivors with a high risk for late effects might require long-term specialist care while regular GP visits might be sufficient for low-risk survivors. It is not known how far survivors agree or not with these medical views. Another limitation is the low response rate, which might indicate that a large number of survivors are not interested in the topic of follow-up care or not aware of the implications of cancer for their future health.
Follow-up care remains an important aspect of long-term survival after childhood cancer, and will continue to grow in importance as survivors age. It is crucial that long-term follow-up not only respects medical guidelines but is organised according to survivors' needs and preferences.
Our study showed that survivors value clinicbased follow-up care by specialists, but also emphasises the necessity to provide care in convenient locations. This needs to be taken into account when considering provision of wellorganised long-term follow-up care for adult survivors of childhood cancer.
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